Yersinia pestis is a Gram-negative
bacterium that is the causative agent of plague and is widely recognized
as a potential biological weapon. Due to the high fatality rate of
plague when diagnosis is delayed, the development of rapid, sensitive,
specific, and cost-effective methods is needed for its diagnosis.
The Y. pestis low calcium response
V (LcrV) protein has been identified as a potential microbial biomarker
for the diagnosis of plague. In this paper, we present a highly sensitive,
paper-based, vertical flow immunoassay (VFI) prototype for the detection
of LcrV and the diagnosis of plague. An antigen-capture assay using
monoclonal antibodies is employed to capture and detect the LcrV protein,
using a colorimetric approach. In addition, the effect of miniaturizing
the VFI device is explored based on two different sizes of VFI platforms,
denoted as “large VFI” and “mini VFI.”
Also, a comparative analysis is performed between the VFI platform
and a lateral flow immunoassay (LFI) platform to exhibit the improved
assay sensitivity suitable for point-of-care (POC) diagnostics. The
analytical sensitivity or limit of detection (LOD) in the mini VFI
is approximately 0.025 ng/mL, that is, 10 times better than that of
the large VFI platform or 80 times over a standard lateral flow configuration.
The low LOD of the LcrV VFI appears to be highly suitable for testing
clinical samples and potentially diagnosing plague at earlier time
points. In addition, optimization of the gold nanoparticle (AuNP)
concentration, nanomaterial plasmonic properties, and flow velocity
analysis could improve the performance of the VFI. Furthermore, we
developed automated image analysis software that shows potential for
integrating the diagnostic system into a smartphone. These methods
and findings demonstrate that the VFI platform is a highly sensitive
device for detecting the LcrV and potentially many other biomarkers.